Q1 FY 2027 saw 37% revenue and 39% EBITDA growth, driven by semaglutide launches, new contracts, and strong biologics momentum. Capacity expansions in DDC, injectables, and softgel support robust FY 2028 guidance, with further growth expected beyond as new markets open.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.